Catalyst Biosciences welcomes Jeanne Jew to its Board of Directors

– USA, CA –  Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the appointment of Jeanne Jew to its Board of Directors.

“We are delighted to welcome Jeanne to our Board of Directors. Jeanne’s deep corporate development expertise will be a tremendous asset as we advance our Protease Medicines pipeline,” said CEO, Dr. Nassim Usman.

About Jeanne Jew

Ms. Jew brings more than 25 years of corporate development experience to her role. She has served as the Chief Business Officer of ALX Oncology Holdings, Inc., since August 2020. Ms. Jew also currently serves as a QB3 Executive Mentor to early-stage life science companies. Before joining ALX, she served for over a decade as Senior Vice President, Business Development of Paratek Pharmaceuticals, and as Senior Vice President, Business Development for KaloBios Pharmaceuticals where she led corporate development, strategy, and market planning. Ms. Jew was previously Vice President, Corporate and Commercial Development at Onyx Pharmaceuticals and was responsible for executing the company’s co-promotion collaboration. Earlier in her career, Ms. Jew also held business development positions at Coulter Pharmaceutical, Scios, Inc., and Genentech, Inc.

Ms. Jew said, “I look forward to supporting the company’s continued growth and working with the team on its strategic planning and business development initiatives. Catalyst’s compelling and innovative portfolio of protease medicines address areas of significant unmet medical need for patients.”

Ms. Jew holds a B.A.in Psychology from Wesleyan University and an M.B.A. from Cornell University.

About Catalyst Biosciences, the Protease Medicines company

Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously administered next-generation engineered coagulation Factor VIIa for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a preclinical C3-degrader program licensed to Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and proteases from our ProTUNE C3b-C4b degrader and ImmunoTUNE C3a-C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways as well as other complement programs in development.

For more information: https://www.catalystbiosciences.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team